In a recent edition of the Journal of the American Medical Association, researchers report that they have found a link between increased risk of Alzheimers disease among men who undergo Androgen Deprivation Therapy at an advanced age for the treatment of Prostate Cancer.
- This study retrospectively analyzed a cohort of 154,089 elderly men with prostate cancer to evaluate the association between exposure to androgen-deprivation therapy (ADT) and dementia or Alzheimer’s disease. Over a follow-up period of at least 10 years, the rate of diagnosis of dementia or Alzheimer’s disease was higher among men who received ADT within 2 years of a prostate cancer diagnosis compared with those who did not receive ADT.
- These findings indicate that exposure to ADT in elderly men with prostate cancer appears to be associated with a subsequent diagnosis of Alzheimer’s disease or dementia over a follow-up of at least 10 years.
The disturbing results of the study point to the need for greater awareness on the part of Prostate Cancer patients when considering undergoing ADT. The authors do not recommend that ADT be abandoned, however as the benefits outweigh the risks.
To read the summary of the research report go to: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2737101